Jeroen Hofenk

Jeroen Hofenk

Ghent, Flemish Region, Belgium
2K followers 500+ connections

About

Serial entrepreneur/scientist (a weird combination :-p) in biotech with a strong focus on…

Activity

Join now to see all activity

Experience

  • Swiftpharma Graphic

    Swiftpharma

    Mechelen, Flemish Region, Belgium

  • -

  • -

    Nederland

  • -

  • -

    Brussel, Brussels Hoofdstedelijk Gewest, België

  • -

    Hasselt, Vlaanderen, België

Patents

  • NANO-ADJUVANT FORMULATIONS AND METHODS OF USE THEREOF

    Issued BE EP20202867.6

    The patent relates to novel nano adjuvants, an influenza vaccine containing the nano adjuvants and a preparation method of the adjuvants. The compositions comprise a plurality of combinatorial nano-particles in a pharmaceutically acceptable carrier. When administered with antigen(s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as cell mediated immunity. The adjuvants are seen with variety of antigens in various mammals irrespective of their…

    The patent relates to novel nano adjuvants, an influenza vaccine containing the nano adjuvants and a preparation method of the adjuvants. The compositions comprise a plurality of combinatorial nano-particles in a pharmaceutically acceptable carrier. When administered with antigen(s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as cell mediated immunity. The adjuvants are seen with variety of antigens in various mammals irrespective of their immune status at the time of administration with the adjuvant and antigen containing composition, e.g. immune naïve or preimmunized status.

  • GENIPIN-CROSSLINKED PDRN-SACRAN BIOPOLYMER SCAFFOLDS

    Filed BE EP20163463.1

    The patent relates to novel anti-inflammatory biopolymer composition for applications in oral hygiene products, wound-care, cosmetics, pharmaceuticals, and food, or can be used as mucoadhesive carrier of APIs. Said invention is particularly useful in the treatment of inflammatory gum diseases, and moreover in the use as a wound healing agent. The novel biopolymers of present invention are PDRN-genipin-Sacran scaffolds, PDRN-Genipin scaffolds, or Sacran-Genipin Scaffolds, whereas genipin…

    The patent relates to novel anti-inflammatory biopolymer composition for applications in oral hygiene products, wound-care, cosmetics, pharmaceuticals, and food, or can be used as mucoadhesive carrier of APIs. Said invention is particularly useful in the treatment of inflammatory gum diseases, and moreover in the use as a wound healing agent. The novel biopolymers of present invention are PDRN-genipin-Sacran scaffolds, PDRN-Genipin scaffolds, or Sacran-Genipin Scaffolds, whereas genipin functions as a natural crosslinker.

  • TRANS-COMPLEMENTARY VECTOR SYSTEM FOR HIGHLY EFFICIENT HETEROLOGOUS GENE EXPRESSION IN PLANTS

    Filed EP23166367

    The invention relates to a trans-complementary system for heterologous expression of genes in plants and comprises a producer vector and a helper vector whereas I) said producer vector is incapable for at least one function needed to cause systemic infection in plants e.g., either by replication, cell-to-cell and/or long distance movement, and II) the helper vector completes the missing function in tandem. Certain producer and helper vectors in one trans-complementary system are derived from…

    The invention relates to a trans-complementary system for heterologous expression of genes in plants and comprises a producer vector and a helper vector whereas I) said producer vector is incapable for at least one function needed to cause systemic infection in plants e.g., either by replication, cell-to-cell and/or long distance movement, and II) the helper vector completes the missing function in tandem. Certain producer and helper vectors in one trans-complementary system are derived from the same virus, or certain producer and helper vectors in one trans-complementary system are derived from different plant viruses. The present invention also provides methods of use, e.g., to improved yield of the heterologous proteins expressed notably in crop plants, and the ease of use of said system.

  • Novel recombinant spider silk-reinforced collagen proteins produced in plants and the use thereof

    Filed EP22166454.3

    The invention relates to novel non-naturally occuring, elastomeric animal-free recombinant fusion biopolymers produced in plants through transient expression. The invention comprises encoding fusion proteins of a non-human scleroprotein with a human collagen, capable of forming hydroxylated triple helix fibers.

  • NOVEL SELECTIVE ANTIMICROBIAL FUSION PEPTIDES

    Filed EU EP21154190

    The patent relates to novel antimicrobial fusion peptides; pharmaceutical compositions comprising the peptides and to uses thereof for treatment or prevention of bacterial infections. The peptides of the present invention are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, which makes them useful in pharmaceutical, healthcare, medical device, food, and personal care applications.

  • NAV1.7 SPECIFIC INHIBITOR AGENT WITH IMPROVED ANALGESIA AND PERIPHERAL DELIVERY

    Filed EU EP20202846.0

    The patent relates to novel recombinant fusion toxin analogues with improved lipid
    membrane interactions, potency for the analgesic sodium channels NaV1.7 and NaV1.8, and peripheral delivery. The fusion protein is produced
    through transiently transformed Nicotiana Benthamiana plants. The patent provides
    methods and pharmaceutical compositions for therapeutic pain management, either via parenteral, oral, nasal, bronchial, or topical administration.

  • INTRANASAL COMPOSITION FOR IMPROVED DELIVERY OF ANTIGENS

    Filed EU EP20202854

    The patent relates to novel vaccine formulations designed for mucosal delivery to the nasal-associated lymphoid tissue, via intranasal administration in various mammals irrespective of their immune status at the time of administration with the adjuvant and antigen containing composition, e.g. immune naïve or preimmunized status. . The association of antigens with mucosal adjuvants and delivery systems is emphasized.

  • PRODUCING ISOTHIOCYANATES FROM CALLUS SUSPENSION CULTURES

    Filed EU WO2020182853

    a method of producing isothiocyanates, The method comprises forming, in a semi-solid or solid callus induction medium, compact callus aggregates from cells obtained from explant material of a Brassica oleracea L. plant. The method comprises transferring cells from the callus aggregates, e.g. transferring the callus aggregates, to a suspension culture in a liquid medium in a shake flask, the liquid medium containing a plurality of elicitors. The method comprises transferring, after culturing in…

    a method of producing isothiocyanates, The method comprises forming, in a semi-solid or solid callus induction medium, compact callus aggregates from cells obtained from explant material of a Brassica oleracea L. plant. The method comprises transferring cells from the callus aggregates, e.g. transferring the callus aggregates, to a suspension culture in a liquid medium in a shake flask, the liquid medium containing a plurality of elicitors. The method comprises transferring, after culturing in the shake flask, cells from the suspension culture to a further suspension culture in a bioreactor containing the elicitors. The method comprises extracting and/or purifying of at least one isothiocyanate from cells obtained from the bioreactor. The elicitors comprise chitosan and salicylic acid to increase accumulation of benzyl isothiocyanate or any other isothiocyanate.

    See patent
  • CANNABINOID PRECURSOR PRODUCTION

    Filed EU WO2020182866

    A nucleic acid molecule is disclosed for transiently transforming a plant to produce Δ9-tetrahydrocannabinolic acid synthase, cannabidiolic acid synthase, and/or cannabichromenic acid synthase and a viral vector comprising such nucleic acid molecule, and to methods for producing THCAS, CBDAS, CBCAS, THCA, CBDA, CBCA, THC, CBD and/or CBC based on transient expression of the nucleic acid sequence in a host plant.

    See patent
  • TRANSCRIPTION FACTOR-MEDIATED PROMOTION OF DIRECT SOMATIC EMBRYOGENESIS

    Filed EU WO2020182857

    A recombinant protein for use in a liquid culture medium for photo-autotrophic micropropagation of Cannabis Sativa L. is disclosed. The recombinant protein comprises a fusion of a growth induction part and a uptake enhancement part. The growth induction part comprises an Arabinogalactan protein and/or a plant transcription factor associated with plant growth and development. The uptake enhancement part comprises a cell penetrating peptide sequence and a nuclear localization signal encoded by…

    A recombinant protein for use in a liquid culture medium for photo-autotrophic micropropagation of Cannabis Sativa L. is disclosed. The recombinant protein comprises a fusion of a growth induction part and a uptake enhancement part. The growth induction part comprises an Arabinogalactan protein and/or a plant transcription factor associated with plant growth and development. The uptake enhancement part comprises a cell penetrating peptide sequence and a nuclear localization signal encoded by the peptide sequence

    See patent
  • REPAIR OF UV-INDUCED DNA LESIONS

    EU WO2020120788

    (EN)

    A composition comprising a recombinant enzyme that comprises a fusion of: a cyclobutane pyrimidine dimer photolyase, a pyrimidine(6-4)pyrimidone photolyase, and a skin penetrating peptide for the repair of pre-mutagenic DNA lesions induced by UV radiation.

    See patent
  • SULFORAPHANE-MELATONIN-LIKE COMPOUND

    EU WO2020043748

    A composition comprising a compound that comprises or consists of a conjugation of 6-hydroxymelatonin and 6- methylsufinylhexyl isothiocyanate is disclosed, as well as this composition for the use as a medicament. Furthermore, this composition for the use in a method of treating and/or preventing an epithelial tissue disease and/or disorder is disclosed.

    See patent

Honors & Awards

  • A sustainable first-in-class multitargeted immunotherapy for the treatment of prostate cancer

    VLAIO

    Together with CimCure B.V. and Amsterdam UMC, SwiftPharma has secured a €1.1 million Eurostars grant for the development of a plant-made multi-targeted vaccination-based immunotherapy for prostate cancer. SwiftPharma obtained a contribution by VLAIO for EURO 321.172 (Grant number HBC.2024.0303)

  • PharmECO - Advancing Safe and Sustainable by Design Practices in Pharmaceutical Manufacturing

    Innovative Health Initiative (IHI JU Call 4, Topic 6)

    This trailblazing 41 million Euro grant, co-funded under the Innovative Health
    Initiative (IHI JU Call 4, Topic 6), is focused on revolutionizing pharmaceutical manufacturing by (i)
    implementing cutting-edge, sustainable, and scalable manufacturing technologies, and (ii)
    establishing harmonized environmental sustainability assessment systems for
    pharmaceuticals and biopharmaceuticals.

    To achieve the ambitious goals of this project, SwiftPharma joins forces with 30
    esteemed…

    This trailblazing 41 million Euro grant, co-funded under the Innovative Health
    Initiative (IHI JU Call 4, Topic 6), is focused on revolutionizing pharmaceutical manufacturing by (i)
    implementing cutting-edge, sustainable, and scalable manufacturing technologies, and (ii)
    establishing harmonized environmental sustainability assessment systems for
    pharmaceuticals and biopharmaceuticals.

    To achieve the ambitious goals of this project, SwiftPharma joins forces with 30
    esteemed international partners, including universities, research institutes, governmental
    bodies, SMEs, and major pharmaceutical companies, each bringing their unique expertise.

    SwiftPharma will play a crucial role in the PharmECO project by providing valuable insights into the sustainability assessment of plant-based biomanufacturing through the scaling of its HyperXpress transient expression technology. The company will collaborate with industry partners to produce three of its model proteins: an antiviral lectin, a monoclonal antibody biosimilar, and a prostate cancer vaccine across different expression platforms. By comparing sustainability hotspots—specific areas within a system, process, product lifecycle, or supply chain that have significant environmental, social, or economic impacts—SwiftPharma aims to identify and prioritize actions and resources to effectively enhance sustainability performance.

  • Beta-Globin Gene Correction Using Peptide Nucleic Acids For The Treatment Of Sickle Cell Anemia

    NIH : NHLBI

    Acknowledged support of the NIH : NHLBI under the SBIR program for $228.490 to test the feasibility of using triplex-forming oligonucleotides to correct the sickle cell disease (SCD) mutation in human CD34+ cells. This technology constituted minimally invasive gene repair, as gene modification occurs in situ via use of the cell's own DNA repair machinery, without the need for viral vectors.

Languages

  • Nederlands

    Native or bilingual proficiency

  • Engels

    Full professional proficiency

  • Frans

    Elementary proficiency

  • Duits

    Elementary proficiency

More activity by Jeroen

View Jeroen’s full profile

  • See who you know in common
  • Get introduced
  • Contact Jeroen directly
Join to view full profile

Other similar profiles

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Others named Jeroen Hofenk

Add new skills with these courses